Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
BioStem Technologies to Host Second Quarter 2026 Financial Results Conference Call on August 12, 2026
-
Applied Biologics expands national commercial payer engagement strategy for XWRAP® to broaden patient access.
-
AI is transforming biologic wound care through earlier diagnosis, better healing predictions, improved therapy selection, and faster clinical research.
-
BioStem Technologies Publicly Files Form 10 Registration Statement with the Securities and Exchange Commission
-
Austin, United States, July 08, 2026 (GLOBE NEWSWIRE) -- The Active Wound Care Market Size was valued at USD 1.32 Billion in 2025 and is expected to reach USD 2.08 Billion by 2035, growing at a CAGR...
-
ECM Therapeutics receives FDA 510(k) clearance for ECMT-100 WMD, validating its extracellular matrix hydrogel platform.
-
Applied Biologics completes enrollment in the CAMPX RCT evaluating XWRAP® for chronic diabetic foot ulcers across 23 SerenaGroup sites.
-
XWRAP showed statistically significant wound closure improvement vs. standard of care alone in the CAMPX RCT — 31% vs. 18% (ITT, p=0.023).
-
BioStem Technologies to Present at the Planet MicroCap Las Vegas 2026 Conference
-
BioStem Technologies Announces Appointment of Three New Members to its Board of Directors